ReutersAstraZeneca widens cancer push with up to $500 million Heptares dealReutersLONDON AstraZeneca expanded its push into cancer immunotherapy on Thursday by striking a deal potentially worth more than $500 million with Sosei's biotech unit Heptares, giving it rights to an experimental treatment. AstraZeneca said it would pay an ...AstraZeneca Secures Licensing Deal With Sosei's Heptares TherapeuticsLondon South EastAstrazeneca to Pay More Than $510 Million for Heptares MedicineBloombergSosei Subsidiary Heptares and AstraZeneca Enter Agreement to Develop Novel ...PharmiWeb.com (press release)all 15 news articles »
AstraZeneca widens cancer push with up to $500 million Heptares deal
Rating: 4.5
Diposkan Oleh: Unknown
